Precision Medicine in Oncology®

New research is carving out a role for ipilimumab and a second CTLA-4-targeting drug, tremelimumab, as combination therapy with potential in a variety of solid tumors. In addition to combinations with other immune checkpoint inhibitors, the agents are being evaluated across a breadth of other strategies.

Despite advances, the majority of patients receiving targeted therapies do not experience radiographic responses, and nearly all patients who initially benefit develop resistance in less than two years.